Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

Atripla™ – HIV therapy in one pill

Authors Julg B, Bogner JR

Published 6 June 2008 Volume 2008:4(3) Pages 573—577

DOI https://doi.org/10.2147/TCRM.S2205

Boris Julg, Johannes R Bogner

Medizinische Poliklinik, Department of Infectious Diseases, University of Munich Medical School, Downtown Campus, Germany

Abstract: In July 2006 Atripla™ was approved by the US Food and Drug Administration (FDA), combining the active ingredients of one NNRTI and two NRTIs. Atripla™ is the first “one-pill-daily” regimen licensed for the treatment of HIV-1 infection in patients older than 18 years. Atripla™ contains efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg. It therefore combines 3 compounds which have been widely used before and which were recommended for initial therapy due to their potency, tolerability, and safety profile. Efficacy and safety data of efavirenz, tenofovir DF, and emtricitabine are reviewed compared with other antiretroviral drugs, which are used as initial therapy for treatment-naive patient.

Keywords: Atripla™antiretroviral therapy, new “one-pill-daily” regimen, review efficacy and safety data

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]